Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.
Publication
, Journal Article
Wallentin, L; Becker, RC; Cannon, CP; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HS; Mahaffey, KW; Pieper, KS; Storey, RF; Steg, PG ...
Published in: Int J Cardiol
January 1, 2014
Duke Scholars
Published In
Int J Cardiol
DOI
EISSN
1874-1754
Publication Date
January 1, 2014
Volume
170
Issue
3
Start / End Page
e59 / e62
Location
Netherlands
Related Subject Headings
- United States Food and Drug Administration
- Platelet Aggregation Inhibitors
- Humans
- Endpoint Determination
- Cardiovascular System & Hematology
- Adenosine
- Acute Coronary Syndrome
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Wallentin, L., Becker, R. C., Cannon, C. P., Held, C., Himmelmann, A., Husted, S., … Harrington, R. A. (2014). Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol, 170(3), e59–e62. https://doi.org/10.1016/j.ijcard.2013.11.003
Wallentin, Lars, Richard C. Becker, Christopher P. Cannon, Claes Held, Anders Himmelmann, Steen Husted, Stefan K. James, et al. “Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.” Int J Cardiol 170, no. 3 (January 1, 2014): e59–62. https://doi.org/10.1016/j.ijcard.2013.11.003.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, et al. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol. 2014 Jan 1;170(3):e59–62.
Wallentin, Lars, et al. “Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.” Int J Cardiol, vol. 170, no. 3, Jan. 2014, pp. e59–62. Pubmed, doi:10.1016/j.ijcard.2013.11.003.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HS, Mahaffey KW, Pieper KS, Storey RF, Steg PG, Harrington RA. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol. 2014 Jan 1;170(3):e59–e62.
Published In
Int J Cardiol
DOI
EISSN
1874-1754
Publication Date
January 1, 2014
Volume
170
Issue
3
Start / End Page
e59 / e62
Location
Netherlands
Related Subject Headings
- United States Food and Drug Administration
- Platelet Aggregation Inhibitors
- Humans
- Endpoint Determination
- Cardiovascular System & Hematology
- Adenosine
- Acute Coronary Syndrome
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology